**DETERMINE**

(**D**etermining **E**xtended **T**herapeutic indications for **E**xisting drugs in **R**are **M**olecularly-defined Indications using a National **E**valuation platform trial)

**Expression of Interest to become a Treatment Arm Lead Investigator for the DETERMINE Trial**

Cancer Research UK’s Centre for Drug Development (CDD) is seeking to appoint Treatment Arm Investigator Leads to join the Project Team and work with the Chief Investigator (Dr Matthew Krebs) to lead the precision medicine DETERMINE trial.

The Treatment Arm Lead Investigator will be expected to take the lead on one of the DETERMINE treatment arms and work closely with the CI, CDD Medical Advisor and wider project team to manage the trial and in particular to help optimising patient recruitment. We are reaching out to motivated Clinicians who may be interested and/or have experience with rare tumour types and are willing to provide oversight to the allocated treatment arm.

There are currently five treatment arms on the DETERMINE trial, four of which are currently open to recruitment TA01 (Alectinib), TA03 (Entrectinib), TA04 (Trasuzumab/Pertuzumab) and TA05 (Vemurafenib/Cobimetinib). TA02 (Atezolizumab) will open once approvals for the first study amendment is approved. In the future we may add further treatment arms whereby you will be able to express an interest – but this will be as and when they come on board.

For further information on the DETERMINE trial please visit:

* DETERMINE website

<https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/determine-overview>

* Clinicaltrials.gov

Master Protocol <https://clinicaltrials.gov/ct2/show/NCT05722886?term=DETERMINE&draw=2&rank=2>

TA01 <https://clinicaltrials.gov/ct2/show/NCT05770037?term=NCT05770037&draw=2&rank=1>

TA02 <https://clinicaltrials.gov/ct2/show/NCT05770102?term=NCT05770102&draw=2&rank=1>

TA03 <https://clinicaltrials.gov/ct2/show/NCT05770544?term=NCT05770544&draw=2&rank=1>

TA04 <https://clinicaltrials.gov/ct2/show/NCT05786716?term=NCT05786716&draw=2&rank=1>

TA05 <https://clinicaltrials.gov/ct2/show/NCT05768178?term=NCT05768178&draw=2&rank=1>

**EOI Invitation**

If you are interested in this opportunity to lead on any of the above treatment arms on the DETERMINE trial, please complete the form below and return to us by 9th June 2023. The DETERMINE team will assess your application and we will aim to respond within a few weeks after the deadline.

Please let us know if you require any additional information about the Investigator lead role or if there are any of your clinical colleagues that might be interested in this opportunity.

Many thanks for your interest in the DETERMINE study.

We look forward to hearing from you.

Your sincerely,

Aida Sarmiento Castro, MSc, PhD

Clinical Study Manager at CRUK’s Centre for Drug Development

**Expressions of Interest**

**Application Form**

Please complete the below form, with your signature, date and return to [DetermineEnquiries@cancer.org.uk](mailto:DetermineEnquiries@cancer.org.uk) as soon as possible.

|  |  |
| --- | --- |
| Applicant Name: | Click or tap here to enter text. |
| Applicant Host Institution: | Click or tap here to enter text. |
| Applicant Title: | Click or tap here to enter text. |
| Study Title: | **DETERMINE (aDvancing gEnomically maTchEd tReatMents IN rare cancErs)** |
| Treatment Arm Applying for: | Choose an item. |
| Describe your research experience or interest in this field (target, biology and/or tumour type) | Click or tap here to enter text. |
| Please add any other information that may be relevant to your Expression of Interest |  |
| Please attach a brief CV detailing relevant research experience and publications |  |